These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 28757207

  • 1. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J.
    Mol Cell; 2017 Aug 03; 67(3):512-527.e4. PubMed ID: 28757207
    [Abstract] [Full Text] [Related]

  • 2. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA, Carmine-Simmen K, Lewis JD, Moore RB, Murray AG.
    PLoS One; 2015 Aug 03; 10(8):e0135245. PubMed ID: 26295809
    [Abstract] [Full Text] [Related]

  • 3. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.
    Mol Cancer Ther; 2015 Nov 03; 14(11):2508-18. PubMed ID: 26358751
    [Abstract] [Full Text] [Related]

  • 4. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct 03; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 6. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.
    Breast Cancer Res; 2014 Jan 23; 16(1):R12. PubMed ID: 24457069
    [Abstract] [Full Text] [Related]

  • 7. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E.
    Mol Cancer Ther; 2015 Apr 23; 14(4):1014-23. PubMed ID: 25673820
    [Abstract] [Full Text] [Related]

  • 8. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF.
    Cell Death Dis; 2014 Mar 13; 5(3):e1114. PubMed ID: 24625973
    [Abstract] [Full Text] [Related]

  • 9. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.
    Oncotarget; 2014 Sep 30; 5(18):8737-49. PubMed ID: 25228590
    [Abstract] [Full Text] [Related]

  • 10. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
    Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ.
    Mol Cancer Ther; 2016 Jul 30; 15(7):1557-67. PubMed ID: 27196780
    [Abstract] [Full Text] [Related]

  • 11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J.
    PLoS One; 2015 Jul 30; 10(7):e0132880. PubMed ID: 26176608
    [Abstract] [Full Text] [Related]

  • 12. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.
    Gynecol Oncol; 2014 Feb 30; 132(2):468-73. PubMed ID: 24316308
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Feb 30; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 14. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J.
    Cell Cycle; 2015 Feb 30; 14(2):232-42. PubMed ID: 25607647
    [Abstract] [Full Text] [Related]

  • 15. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.
    Oncotarget; 2015 Sep 22; 6(28):26230-41. PubMed ID: 26213847
    [Abstract] [Full Text] [Related]

  • 16. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
    May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang WL, Lazar AJ, Torres KE.
    Cancer Biol Ther; 2017 Oct 03; 18(10):816-826. PubMed ID: 29099264
    [Abstract] [Full Text] [Related]

  • 17. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H, Shang C, Wang M, Shen T, Kong L, Yu C, Ye Z, Luo Y, Liu L, Li Y, Huang S.
    Biochem Pharmacol; 2016 Sep 15; 116():39-50. PubMed ID: 27396756
    [Abstract] [Full Text] [Related]

  • 18. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S, Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam MF, Canan SS, Worland P, Sankar S, Raymon HK.
    Mol Cancer Ther; 2015 Jun 15; 14(6):1295-305. PubMed ID: 25855786
    [Abstract] [Full Text] [Related]

  • 19. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.
    PLoS One; 2012 Jun 15; 7(7):e40439. PubMed ID: 22808163
    [Abstract] [Full Text] [Related]

  • 20. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC.
    Breast Cancer Res Treat; 2014 Apr 15; 144(2):287-298. PubMed ID: 24562770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.